Dyspepsia in primary care: acid suppression as effective as prokinetic therapy. A randomized clinical trial

Scand J Gastroenterol. 2001 Sep;36(9):942-7. doi: 10.1080/003655201750305459.

Abstract

Background: While dyspeptic patients in primary care often receive empirical treatment with antisecretory drugs, a substantial number suffer from motility disturbances which may be associated with their complaints. We aimed to compare the effectiveness of treatment with antisecretory treatment with a prokinetic agent in uninvestigated dyspepsia.

Methods: 563 patients presenting dyspeptic complaints to the general practitioner with a low likelihood of organic (ulcer, reflux or malignant) disease, i.e. absence of alarm symptoms or a history of peptic ulcer disease or gastro-oesophageal reflux disease were included. They entered a randomized, double-blind trial of 4 weeks of ranitidine 150 mg bid compared with 4 weeks of cisapride 10 mg bid, with 3 months follow-up. Treatment failure was defined as no response to treatment or a relapse of symptoms within the follow-up period. Also studied were the effect on dyspepsia severity, response to treatment after 4 weeks, and time to relapse.

Results: For all randomized patients, the incidence of overall treatment success after 3 months follow-up with antisecretory treatment was 107/271 (39.5%) and with a prokinetic agent 122/282 (43.3%); the risk difference was 3.8% (95% CI -4.4% to 12.0%); the difference in symptom severity score after 4 weeks of treatment was 0.3; 95% CI -0.4% to 1.0%. For patients responding to 4 weeks of treatment, relapse-free time was 86 days in the prokinetic group and 79 days in the acid suppression group (P = 0.005).

Conclusions: Antisecretory and prokinetic therapies are equally effective in primary care patients with uninvestigated dyspeptic complaints, though relapse rates are lower in patients treated with prokinetic treatment.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cisapride / therapeutic use*
  • Cohort Studies
  • Double-Blind Method
  • Dyspepsia / drug therapy*
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents / therapeutic use*
  • Histamine H2 Antagonists / therapeutic use*
  • Humans
  • Male
  • Multivariate Analysis
  • Ranitidine / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Gastrointestinal Agents
  • Histamine H2 Antagonists
  • Ranitidine
  • Cisapride